ATUM to offer Protein Synthesis Platform to COVID-19 test tool developers
Category: #health  | By Mateen Dalal  | Date: 2020-03-27 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

ATUM to offer Protein Synthesis Platform to COVID-19 test tool developers

As the coronavirus pandemic reaches community level, prominent companies have come forward to aid medical researchers in accelerating their drug development process. ATUM, an American biotechnology firm, recently made a similar move when it revealed that it would offer access to its Leap-In Transposase® protein production solution for free to all academic and commercial laboratories that are creating vaccines, new protein-based therapies and diagnostic tools for combating the COVID-19.

With a broad range of antibodies, viral proteins, and interleukins along with other related protein molecules presently being tested under COVID-19-related trials, ATUM’s biological Leap-In platform would facilitate rapid development of commercial-grade protein up to kilogram levels.

Apparently, the effective cell-based protein production could play a vital role in ramping up the manufacturing of protein-based therapeutics, diagnostic tests, and vaccines.

ATUM’s Leap-In Transposase solution also allows a stable and rapid gene integration for the expression of complex and simple proteins from mammalian hosts. Additionally, antibody production titers surpassing 5g/L could be attained under a few weeks. In fact, the platform is being used by leading pharmaceutical and biotechnology firms across the world.

Meanwhile, other biotech firms are also boosting their developmental efforts in order to formulate a treatment for COVID-19. For instance, San Francisco-based biotech firm, Genentech is forming strategic alliance with the FDA to run a phase-three trial that examines if its existing medicines are effective enough to combat the virus.

Commenting on the move, Dr. Levi Garraway, Chief Medical Officer, Genentech, said that the company is commencing a clinical study with one of its drugs called Actemra to test if it is effective against COVID-19 pneumonia.

As for Claes Gustafsson, Co-founder, ATUM, the firm’s labs are busier than normal and have even reached out to other local labs for finding a cure for this disease.

Source Credit: https://apnews.com/Business%20Wire/e8918decc19f49289d7f70865626c041

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Microsoft investigates Teams and Outlook outage that left users disrupted

Microsoft investigates Teams and Outlook outage that left users disrupted

By Mateen Dalal

Microsoft, the U.S.-based technology frontrunner, reportedly investigating an outage that prevented thousands of customers from accessing services like Teams and Outlook. Apparently, the tech giant did not disclose the number of users that were im...

UK: Budget & basic items’ cost in supermarkets soar 20.3% in December

UK: Budget & basic items’ cost in supermarkets soar 20.3% in December

By Mateen Dalal

Britishers who rely on the budget-friendly aisles of supermarkets reportedly saw the biggest increases in food prices in the months leading up to Christmas, significantly outpacing those for luxury as well as premium brands, as per a survey. Accor...

Sun Cable shuts as $21B solar project to power S’pore hangs in balance

Sun Cable shuts as $21B solar project to power S’pore hangs in balance

By Mateen Dalal

Sun Cable, the Singapore-based solar energy company, has reportedly entered voluntary administration, despite the financial support it received from billionaire investors. The company was supposed to be working on a A$30 billion (US$21 billion) solar...